![](https://cdn.sanity.io/images/0vv8moc6/curetoday/4e25390774dc49a766bc17fa480be8d454ec2c38-3234x3170.jpg?fit=crop&auto=format)
THIO-Libtayo Regimen Is ‘Encouraging’ for Relapsed NSCLC
A regimen consisting of the novel drug THIO with Libtayo (cemiplimab) led to positive outcomes in patients with non-small cell lung cancer (NSCLC) that was previously treated with two or more standard-of-care options, according to findings from the phase 2 …